Phaseline

Targets › TMEM173

TMEM173 (Stimulator of interferon genes protein): drug programs, companies and trials

3 programs from 3 companies in 14 trials: 6 Phase 1, 5 Phase 2, 3 Phase 3; Oncology; next expected readout Dec 2026.

Key innate immune signaling adapter that promotes the production of type I interferon (IFN-alpha and IFN-beta) in response to the presence of DNA from bacteria and viruses in the cytosol. Innate immune response is triggered by non-CpG double-stranded DNA from viruses and bacteria delivered to the cytoplasm, which induces production of cyclic dinucleotides that bind and activate STING1: STING1 recognizes and binds…. (UniProt, Q86WV6)

Open in Phaseline: the race on TMEM173, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
PfizerPF-08634404
Stimulator of Interferon genes (STING) agonist
TMEM173Phase 3Advanced Non-Small Cell Lung Cancer; Endometrial Neoplasms; Intestinal Neoplasms; Small Cell Lung Cancer …Oct 2027
RenJi HospitalIparomlimab and Tuvonralimab (QL1706)
STING agonist
TMEM173Phase 2HR-positive/HER2-negative Breast CancerDec 2026
Memorial Sloan Kettering Cancer CenterCRD3874-SI
STING agonist
TMEM173Phase 1Acute Myeloid Leukemia; SarcomaJun 2028

Conditions

Advanced Non-Small Cell Lung Cancer (1) Endometrial Neoplasms (1) Intestinal Neoplasms (1) Small Cell Lung Cancer (1) Carcinoma (1) Small Cell Lung Cancer (SCLC) (1) Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction , or Esophageal Adenocarcinoma (1) Carcinoma, Hepatocellular (1) Carcinoma, Renal Cell (1) Urothelial Cancer (1) Advanced/Metastatic Non-Small Cell Lung Cancer (1) Acute Myeloid Leukemia (1)

Modalities

mixed (2), small molecule (1)

Companies

Pfizer (1) Memorial Sloan Kettering Cancer Center (1) RenJi Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.